Cyclerion Therapeutics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | no data |
CEO ownership | n/a |
Management average tenure | no data |
Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Cyclerion stock tanks 32% on workforce reduction, clinical development refocus
Oct 06We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Aug 09We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Mar 03Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Oct 26Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021
Jun 21Cyclerion climbs on a series of insider purchases
Jun 08Cyclerion updates on clinical trial progress at webinar
Apr 28Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?
Mar 09What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
Jan 28Cyclerion Therapeutics +10.5% after prelim reports
Jan 13Cyclerion Therapeutics announces promotions
Dec 21Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?
Dec 20Cyclerion Therapeutics reports Q3 results
Nov 05CEO
Cyclerion Therapeutics has no CEO, or we have no data on them.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Director | 5.7yrs | US$169.80k | 14.91% $ 1.2m | |
Independent Chairman | 3.7yrs | US$131.08k | 1.98% $ 164.5k | |
Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
Independent Director | 2.4yrs | US$57.30k | 0.79% $ 65.8k | |
Independent Director | less than a year | US$43.60k | 0.79% $ 65.8k | |
Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
Chair of Scientific Advisory Board | no data | US$366.78k | no data | |
Member of Clinical Advisory Board | 3.9yrs | no data | no data | |
Member of Clinical Advisory Board | 3.9yrs | no data | no data | |
Member of Clinical Advisory Board | 3.9yrs | no data | no data | |
Member of Clinical Advisory Board | 3.9yrs | no data | no data |
3.9yrs
Average Tenure
69yo
Average Age
Experienced Board: CYCN's board of directors are considered experienced (3.9 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 05:01 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyclerion Therapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Pete Stavropoulos | Cantor Fitzgerald & Co. |
Martin Auster | Credit Suisse |
Joon So Lee | Truist Securities |